Opinion|Videos|December 5, 2025

Payer and Prior Authorization Barriers

Panelists discuss how payer controls and prior authorization policies delay and derail LDL-lowering therapy.

Panelists discuss how payer utilization management and prior authorization processes delay therapy initiation and contribute to high abandonment rates.

The paperwork burden discourages prescribers and frustrates patients, often interrupting continuity of care. Panelists highlight that these barriers disproportionately affect lower-income populations and smaller practices.

They recommend policy reforms that balance cost control with clinical flexibility, enabling timely treatment for high-risk individuals.

Newsletter

Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.


Latest CME

Brand Logo

259 Prospect Plains Rd, Bldg H
Cranbury, NJ 08512

609-716-7777

© 2025 MJH Life Sciences®

All rights reserved.

Secondary Brand Logo